Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31187
Title: Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project
Authors: BRAEYE, Toon 
Emborg, Hanne-Dorthe
Llorente-Garcia, Ana
Huerta, Consuelo
Martin-Merino, Elisa
Duarte-Salles, Talita
Danieli, Giorgia
Tramontan, Lara
Weibel, Daniel
McGee, Chris
Villa, Marco
Gini, Rosa
Lehtinen, Matti
Titievsky, Lina
Sturkenboom, Miriam
Issue Date: 2020
Publisher: ELSEVIER SCI LTD
Source: VACCINE, 38 (16) , p. 3243 -3254
Abstract: Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies. Methods: A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990-2000 and influenza-vaccine for birth years 1920-1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server. Results: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997-2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain). Conclusions: We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates.
Notes: Braeye, T (reprint author), Sciensano, Rue Juliette Wytsman 14, B-1050 Brussels, Belgium.
toon.braeye@sciensano.be
Other: Braeye, T (reprint author), Sciensano, Rue Juliette Wytsman 14, B-1050 Brussels, Belgium. toon.braeye@sciensano.be
Keywords: Vaccination coverage;Influenza vaccines;Papillomavirus vaccines;Measles vaccines;Probability
Document URI: http://hdl.handle.net/1942/31187
ISSN: 0264-410X
e-ISSN: 1873-2518
DOI: 10.1016/j.vaccine.2020.02.082
ISI #: WOS:000525317600011
Rights: 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
toon.pdfPublished version711.02 kBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

1
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

10
checked on Apr 22, 2024

Page view(s)

30
checked on Sep 7, 2022

Download(s)

12
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.